Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer

[1] ALIMANDI M, 1995, ONCOGENE, V10, P1813

[2] Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 11 - 21

[3] The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J]. FEBS LETTERS, 1997, 410 (01) : 83 - 86

[4] Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes [J]. ONCOGENE, 1998, 16 (06) : 737 - 746

[5] ErbB receptor tyrosine kinase inhibitors as therapeutic agents [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 : D1926 - D1940

[6] Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (37) : 23247 - 23254

[7] Azemar M, 2000, INT J CANCER, V86, P269, DOI 10.1002/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO

[8] 2-8

[9] Baselga J, 1999, SEMIN ONCOL, V26, P78

[10] Baselga J, 2001, J CLIN ONCOL, V19, p41S

[1] ALIMANDI M, 1995, ONCOGENE, V10, P1813

[2] Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 11 - 21

[3] The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J]. FEBS LETTERS, 1997, 410 (01) : 83 - 86

[4] Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes [J]. ONCOGENE, 1998, 16 (06) : 737 - 746

[5] ErbB receptor tyrosine kinase inhibitors as therapeutic agents [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 : D1926 - D1940

[6] Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (37) : 23247 - 23254

[7] Azemar M, 2000, INT J CANCER, V86, P269, DOI 10.1002/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO

[8] 2-8

[9] Baselga J, 1999, SEMIN ONCOL, V26, P78

[10] Baselga J, 2001, J CLIN ONCOL, V19, p41S